E-LIB Suche - Ergebnisse für: Raz, I

1

Short-term effectiveness of dapagliflozin versus DPP-4 inhi..:

Morieri, M. L. ; Raz, I. ; Consoli, A....
Journal of Endocrinological Investigation. 46 (2023) 7 - p. 1429-1439 , 2023

Link: https://doi.org/10.1007/..

2

Effects of dapagliflozin on cardiovascular and kidney event..:

Moura, F ; Wiviott, S ; Chertow, G...
European Heart Journal. 43 (2022) Supplement_2 - p. , 2022

Link: https://doi.org/10.1093/..

3

Influence of cardiovascular drugs on the efficacy and safet..:

Oyama, K ; Raz, I ; Cahn, A...
European Heart Journal. 42 (2021) Supplement_1 - p. , 2021

Link: https://doi.org/10.1093/..

4

Efficacy and safety of dapagliflozin according to baseline ..:

Furtado, R ; Raz, I ; Goodrich, E.L..
European Heart Journal. 41 (2020) Supplement_2 - p. , 2020

Link: https://doi.org/10.1093/..

5

410Heart failure risk stratification and efficacy of dapagl..:

Berg, D ; Wiviott, S ; Scirica, B...
European Heart Journal. 40 (2019) Supplement_1 - p. , 2019

Link: https://doi.org/10.1093/..

6

192Effect of dapagliflozin on cardiovascular outcomes in pa..:

Zelniker, T A ; Raz, I ; Mosenzon, O...
European Heart Journal. 40 (2019) Supplement_1 - p. , 2019

Link: https://doi.org/10.1093/..

7

Sécurité du liraglutide versus placebo chez les diabétiques..:

Marre, M. ; Mann, J. ; Fonseca, V....
Annales d'Endocrinologie. 79 (2018) 4 - p. 267 , 2018

Link: https://doi.org/10.1016/..

8

Le liraglutide diminue les évènements cardiovasculaires maj..:

Marre, M. ; Poulter, N. ; Mann, J....
Annales d'Endocrinologie. 79 (2018) 4 - p. 265 , 2018

Link: https://doi.org/10.1016/..

9

Creating Individualized HBA1C Targets Using Predictive Mode..:

Karpati, T ; Curtis, BH ; Feldman, B...
Value in Health. 20 (2017) 9 - p. A733 , 2017

Link: https://doi.org/10.1016/..

10

LEADER 5: prevalence and cardiometabolic impact of obesity ..:

on behalf of the LEADER investigators ; Masmiquel, L. ; Leiter, L. A....
Cardiovascular Diabetology. 15 (2016) 1 - p. , 2016

Link: https://doi.org/10.1186/..

11

Response to: 'baseline differences in SAVOR trial' – prespe..:

Raz, I. ; Cahn, A. ; Mosenzon, O...
Diabetes, Obesity and Metabolism. 17 (2015) 12 - p. 1203-1204 , 2015

Link: https://doi.org/10.1111/..

12

Retraction Note: Abstracts of the 50th Annual Meeting of th..:

DIA-AID Study Group ; Elias, D. ; Avron, A....
Diabetologia. 58 (2015) 5 - p. 1141-1141 , 2015

Link: https://doi.org/10.1007/..

13

Achieving the composite endpoint of glycated haemoglobin <7..:

Dungan, K. M. ; Raz, I. ; Skrivanek, Z...
Diabetes, Obesity and Metabolism. 18 (2015) 1 - p. 49-55 , 2015

Link: https://doi.org/10.1111/..

14

Frequency of cancer events with saxagliptin in the SAVOR-TI..:

Leiter, L. A. ; Teoh, H. ; Mosenzon, O....
Diabetes, Obesity and Metabolism. 18 (2015) 2 - p. 186-190 , 2015

Link: https://doi.org/10.1111/..

15

Impact of treatment with saxagliptin on glycaemic stability..:

Leibowitz, G. ; Cahn, A. ; Bhatt, D. L....
Diabetes, Obesity and Metabolism. 17 (2015) 5 - p. 487-494 , 2015

Link: https://doi.org/10.1111/..